Clinical trials: Prostatic Disease
Prostate Cancer
Evaluation of the SENSEI® Laparoscopic Tethered Gamma Probe for 99mTc-nanocolloid Sentinel Lymph Node Biopsy in Prostate Cancer
This study is a prospective, open label, single-arm study to examine the performance and safety of the SENSEI® laparoscopic tethered gamma probe in patients undergoing 99mTc-nanocolloid SLNB for prostate cancer (PCa) during RP…
- Trial name
- LPM-012 (NCT04632251)
- Testing
- SENSEI®
- Where
- 4 sites in Belgium, France and 2 more
- Volunteers
- 56 people
- Sponsor
- Lightpoint Medical Limited
Prostate Cancer
dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy
The purpose of this study is to conduct a US Pilot study of dMD-002 as a peripheral nerve repair sheet in patients with cavernous nerve injury following radical prostatectomy.
- Trial name
- NCT07564102
- Testing
- dMD-002, Control
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Mochida Medical USA, Inc.
Prostate Cancer, Castration-resistant Prostate Cancer
A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC
The aim of this trial is to study the tolerance, pharmacokinetics (PK) and efficacy of SHR2554 alone or in combination with SHR3680 in the treatment of patients with metastatic Castration Resistant Prostate Cancer.
- Trial name
- NCT03741712
- Testing
- SHR3680, SHR2554
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Benign Prostatic Hyperplasia
Study to Investigate the Efficacy and Safety of GL2702 GLARS-NF1tablet and Harnal-D - Tablet in BPH Patients With LUTS
Study to investigate the efficacy and safety of GL2702 GLARS-NF1tablet and Harnal-D - tablet in benign prostatic hyperplasia patients with lower urinary tract symptomatic
- Trial name
- GL2702 (NCT02303769)
- Testing
- Tamsulosin HCL 0.4mg, Tamsulosin HCL 0.2mg
- Where
- South Korea
- Volunteers
- 309 people
- Sponsor
- GL Pharm Tech Corporation
Prostate Cancer
Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
The purpose of this study is to evaluate the safety and efficacy of the Vanquish Water Vapor Ablation Device ("Vanquish") in treating subjects with Gleason Grade Group 2 (GGG2) localized intermediate-risk prostate cancer.
- Trial name
- VAPOR 2 (NCT05683691)
- Testing
- Vanquish System
- Where
- 25 sites in United States
- Volunteers
- 400 people
- Sponsor
- Francis Medical Inc.
Prostate Cancer
The Plenaxis® Experience Study
Praecis is currently conducting a 2000 patient Experience Study; this is a Phase IV commitment postmarketing safety study in the Food and Drug Administration (FDA) indicated population of patients receiving Plenaxis®.
- Trial name
- NCT00103623
- Testing
- Plenaxis
- Where
- 60 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- PRAECIS Pharmaceuticals Inc.
Prostate Cancer, Hirsutism
Relative Bioavailability Study of Bicalutamide 50 mg Tablet and Casodex Following a 50 mg Dose in Healthy Subjects Under Fasting Conditions
The purpose of this study is to demonstrate the relative bioavailability of Bicalutamide 50 mg tablet and Casodex following a 50 mg dose in healthy subjects under fasting conditions.
- Trial name
- NCT00959335
- Testing
- Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA), Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Sandoz
Benign Prostatic Hyperplasia
The Safety and Effectiveness of UroLift: LIFT Pivotal Study
The purpose of the study is to evaluate the safety and effectiveness of the UroLift(R) System when used in subjects with symptomatic benign hyperplasia (BPH).
- Trial name
- LIFT (NCT01294150)
- Testing
- UroLift System, Cystoscopy, Crossover
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 206 people
- Sponsor
- NeoTract, Inc.
Locally Advanced or Metastatic Prostate Cancer.
Depiction of Prostate Cancer Treatment Alternatives in Greece
A retrospective, registry analysis of the socio-economic and demographic characteristics of patients suffering from locally advanced or metastatic prostate cancer, as well as the depiction of the therapeutic algorithms followed…
- Trial name
- NCT00733213
- Where
- 4 sites in Greece
- Volunteers
- 310 people
- Sponsor
- AstraZeneca
Prostate Cancer
A Safety Study in Patients With Advanced Prostate Cancer Treated With FIRMAGON
This study is a large observational study, set-up to observe how long-term treatment with FIRMAGON (hormone regulator) compare to other treatments in regards to cardiovascular events, changes in bone density, changes in blood…
- Trial name
- NCT01234350
- Where
- 160 sites in Belgium, Denmark and 13 more
- Volunteers
- 1,493 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)
The objective of this study is to evaluate the safety and efficacy of priming vaccinations, and subsequent boosting vaccinations with GVAX® Vaccine for Prostate Cancer.
- Trial name
- NCT00140374
- Testing
- Immunotherapy allogeneic GM-CSF secreting cellular vaccine
- Volunteers
- 36 people
- Sponsor
- Cell Genesys
Solid Tumors, Prostate Cancer
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
This Phase I trial combines ADI-PEG 20 with docetaxel in patients with advanced solid tumors with emphasis on castration resistant prostate cancer (CRPC).
- Trial name
- NCT01497925
- Testing
- ADI-PEG 20
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Polaris Group
Prostate Cancer
A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer
The purpose of this study is to determine the benefit of enzalutamide versus placebo as assessed by overall survival and progression-free survival in patients with progressive metastatic prostate cancer who have failed androgen…
- Trial name
- PREVAIL (NCT01212991)
- Testing
- Enzalutamide
- Where
- 269 sites in United States, Australia and 20 more
- Volunteers
- 1,717 people
- Sponsor
- Pfizer
Benign Prostatic Hyperplasia
Observational Study to Evaluate Effect of Thrupas® Capsule on Cardiovascular System
To evaluate effect on cardiovascular system(blood pressure) when Thrupas® capsule is administered every day for 12 weeks in patients with Lower Urinary Tract Symptoms suggestive of Benign Prostatic Hyperplasia
- Trial name
- CV (NCT02029560)
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- JW Pharmaceutical
Prostate Cancer
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for…
- Trial name
- NCT00833248
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 246 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
GE-148-002: A Phase 2, Open-label, Single-Center Study to Assess GE-148 (18F) Injection PET Imaging to Detect Localized Prostate Cancer
Background: GE-148 (18F) is a new drug that is designed to attach to prostate cancer cells. Researchers are interested in combining the drug with a small amount of radioactive material to allow prostate cancer lesions to appear…
- Trial name
- NCT01176513
- Testing
- GE-148 (18F)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- GE Healthcare
Prostatic Hyperplasia
Study to Compare the Efficacy and Safety of Combination Treatment With Dutasteride and Tamsulosin With Tamsulosin Monotherapy, in Men With Moderate to Severe Benign Prostatic Hyperplasia
This is a multicentre, randomised, double-blind, parallel group study in Asian subjects. The aim of the study is to investigate whether combination therapy with dutasteride and tamsulosin is more effective than tamsulosin…
- Trial name
- NCT02058368
- Testing
- Dutasteride 0.5mg capsules, Tamsulosin 0.2mg tablets
- Where
- 46 sites in China, Japan and 2 more
- Volunteers
- 607 people
- Sponsor
- GlaxoSmithKline
Breast Cancer, Ovarian Cancer
Investigating the Diagnostic Potential of Tear Proteins in Cancer - A Pilot Study
This Pilot Study is to investigate the tear proteins in a multitude of cancer types and indulge in biomarker discovery to manufacture simple, accurate, and novel tear-based diagnostic tests.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- NCT05223218
- Testing
- Schirmer strip, a Class I Medical Device typically used to test for dry eye.
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Namida Lab
Bladder Cancer, Breast Cancer
A Study Comparing Oral Picoplatin With Intravenous Picoplatin in Subjects With Solid Tumors
Picoplatin is a new platinum-based chemotherapy drug that has been studied in a variety of cancers. Phase 1 and 2 studies have demonstrated that picoplatin may be effective in patients whose cancer returns or does not improve…
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastrointestinal Neoplasm
- Trial name
- NCT00465725
- Testing
- Picoplatin
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Poniard Pharmaceuticals
Phase 1, Healthy
EC905 Pharmacokinetic Profile Study
A study to compare the pharmacokinetics of tamsulosin HCl and solifenacin succinate after co-administration of single entity tablets and of the combination tablet EC905 under steady state conditions at three dose strengths.
- Conditions
- Phase 1, Healthy, Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
- Trial name
- NCT02634489
- Testing
- Tamsulosin HCl, Solifenacin Succinate, EC905
- Where
- Netherlands
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Astellas Pharma Europe B.V.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.